Rafi R. Kazi, M.D.
No ratings currently available, see text in Ratings section below for explanation.
Contact
About Me
Certified Specialties
Pediatric Hematology-Oncology - American Board of Pediatrics
Pediatrics - American Board of Pediatrics
Faculty Appointments
Assistant Professor - Department of Pediatrics, Hematology and Oncology (SMD)
Credentials
Residency & Fellowship
Fellowship, Pediatric Hematology-Oncology, Emory University Hospital. 2017 - 2020
Residency, Pediatrics, Strong Memorial Hospital/University of Rochester. 2015 - 2017
Internship, Pediatrics, Strong Memorial Hospital/University of Rochester. 2014 - 2015
Education
MD | University of Arkansas College of Medicine. 2014
Research
Clinical Trials
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Lead Researcher: Rafi R Kazi
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in che...
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Lead Researcher: Rafi R Kazi
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatmen...
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly
Lead Researcher: Rafi R Kazi
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phe...
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Lead Researcher: Rafi R Kazi
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Umbrella Long-Term Follow-Up Protocol
Lead Researcher: Rafi R Kazi
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children'...
Ratings & Comments
At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.